CONTINUATION PAGE: STAY WITHIN MARGINS INDICATED 
Principal Investigator/Program Director (Last, first, middle): 
Wimperis JZ, Gottlieb D, Duncombe AS, Heslop HE, Prentice HG, Brenner MK. Requirements 
for the adoptive transfer of antibody responses to a priming antigen in man. J Immunol 
144:541-547, 1990 . 
Duncombe AS, Meager A, Prentice HG, Grundy JE, Heslop HE, Hoffbrand AV, Brenner MK. 
Gamma interferon and tumour necrosis factor production following bone marrow 
transplantation is augmented by exposure to marrow fibroblasts infected with CMV. 
Blood 76:1046-1053, 1990. 
Gottlieb DJ, Cryz SJ, Prentice HG, Duncombe AS, Brenner MK. Immunity against multiple 
Pseudomonas serotypes adoptively transferred to bone marrow transplant recipients. 
Blood 76:2470-2475, 1990. 
Heslop HE, Bianchi ACM, Cordingley FT, Turner M, Del Mel WCP, Hoffbrand AV, Brenner MK. 
Effects of o-interferon on autocrine growth factor loops in B lymphoproliferative 
disorders. J Exp Med 172:1729-1734, 1990. 
Bello-Fernandez C, Bird C, Heslop HE, Gottlieb DJ , Reittie JE, Rill DM, Holland M, Prentice HG, 
Brenner MK. Homeostatic Action of IL-4 on Endogenous and Recombinant IL-2 Induced 
Activated Killer Cell Function. Blood 77:1283-1289, 1991. 
Oblakowski P, Bello-Fernandez C, Reittie JE, Heslop HE, Galatowicz G, Veys P, Wilkes S, 
Prentice HG, Hoffbrand AV, Brenner, MK. Possible mechanism of selective killing of 
myeloid leukemia blast cells by lymphokine-activated killer cells. Blood 77: 1 996-2001 , 
1991. 
Brenner M, Mirro J Jr, Hurwitz C, Santana V, Ihle J, Krance R, Ribeiro R, Roberts WM, 
Mahmoud H, Schell M, Garth K. Autologous bone marrow transplant for children with 
AML in first complete remission: Use of marker genes to investigate the biology of 
marrow reconstitution and the mechanism of relapse. Human Gene Ther 2:137-159, 
1991. 
Rill DR, Buschle M, Foreman NK, Bartholomew C, Moen RC, Santana VM, Ihle JN, Brenner MK. 
Retrovirus mediated gene transfer as an approch to analyze neuroblastoma relapse after 
autologous marrow transplantation. Human Gene Ther 3:129-136, 1992. 
Duncombe AS, Grundy JE, Oblakowski P, Prentice HG, Gottlieb DJ, Roy DM, Reittie JE, Bello- 
Fernandez C, Hoffbrand AV, Brenner MK. Bone marrow transplant recipients have 
defective MHC unrestricted cytotoxic responses against cytomegalovirus in comparison 
with Epstein-Barr virus: the importance of target cell expression of lymphocyte-function- 
associated antigen (LFA1). Blood 79:3059-3066, 1992. 
Rencher SD, Hanif I, Heslop HE, Turner V, Brenner MK, Hurwitz JL. Reconstitution of the T-cell 
receptor a0 repertoire in recipients of allogeneic bone marrow transplant. Bone Marrow 
Transplant 10:521-527, 1992. 
Buschle M, Campana D, Carding VR, Hoffbrand AV, Brenner MK. Interferon-yinhibits apoptosis 
in B cell chronic lymphocytic leukemia. J Exp Med 177:213-218, 1993. 
Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J Jr, Anderson WF, Ihle JN. Gene-marking 
to trace origin of relapse after autologous bone marrow transplantation. Lancet 341 :85- 
86 , 1993. 
Williams LL, Rooney CM, Conley ME, Brenner MK, Krance RA, Heslop HE. Correction of 
Duncan's syndrome by allogeneic bone marrow transplantation. Lancet 342:587-588, 
1993. 
Brenner MK, Rill DR, Holladay MS, Heslop HE, Moen RC, Busche M, Krance RA, Anderson WF, 
Ihle JN. Gene marking to determine whether autologous marrow infusion restores long- 
term haemopoiesis in cancer patients. Lancet 342:1 134-1 137, 1993. 
Recombinant DNA Research, Volume 19 
[5131 
